Despite the recognized need for new antimicrobials for clinical use, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years. Inappropriate prescribing of antibiotics has been attributed to a number of causes, including people who insist on antibiotics, physicians who simply prescribe them as they feel they do not have time to explain why they are not necessary, and physicians who do not know when to prescribe antibiotics or else are overly cautious for medical legal reasons.
New strategies in the treatment of infections are crucial, as antibiotic resistance (antimicrobial resistance, AMR) is emerging. This resistance will increase over the coming years and decades because of the excessive use of traditional antibiotics in humans and animals.
Given the fact that it takes at least 10 years to deliver efficacious medicines to patients it is crucial that the research delivers new antimicrobial agents as soon as possible. Since Madam Therapeutics has made significant progress in the development of it’s own SAAP portfolio of antibiotics we believe that we can make an early contribution to the delivery of new antibiotics to the world
Our AMPs form such a new approach to overcome antimicrobial resistance. Our AMPs do not have to developed for scratch, and have completed most of the pre-clinical development. This will save many (costly) years of development.